ArticleScientific reports2026
Bioactive pigment production by marine bacteria from Colombian estuarine and deep-sea environments.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The marine environment is a reservoir of microbial diversity with high biotechnological potential. Natural pigments, such as some secondary metabolites, are of particular interest due to their ease of microbial cultivation and recovery, as well as their diverse biological activities. This study aimed to explore pigment production by bacteria isolated from estuarine and deep-sea environments in Colombia and evaluate their antimicrobial potential. Six from twenty-six isolates were tested for pigment production, and were taxonomically assigned to the genera Streptomyces (four), Pseudomonas (one), and Serratia (one). The pigment extracts demonstrated strong antimicrobial activity, with inhibition exceeding 90% against Methicillin-resistant Staphylococcus aureus (MRSA) and Candida albicans. Streptomyces sp. INV ACT17, isolated from marine sediments at 1,400 m depth was the most promising strain. Further characterization identified ISP-2 medium with a 1.5 mg/mL inoculum as optimal for pigment production. FTIR and molecular network dereplication analysis using UHPLC-MS/MS suggested actinomycin D as the major pigmented compound, a finding subsequently confirmed by NMR spectroscopy. Kinetic studies revealed a non-growth-associated profile with maximum production (762 ± 59 mg/L) after 196 h, and achieved a IC50 0.12 µg/mL against MRSA. These findings highlight deep–sea actinobacteria as valuable sources of bioactive pigments and establish Streptomyces sp. INV ACT17 is a promising candidate for natural antimicrobial discovery and development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.